吕续成,沈雳,洪斌,葛均波

• 1:复旦大学附属中山医院青浦分院心内科
• 2:上海市心血管病研究所复旦大学附属中山医院心内科

摘要(Abstract)：

<正>生物可吸收支架(bioresorbable scaffold,BRS)被认为是继经皮冠状动脉腔内成形术(percutaneous transluminal coronary angioplasty,PTCA)、裸金属支架(bare metal stent,BMS)、药物洗脱支架(drug eluting stent,DES)之后,经皮冠状动脉治疗(percutaneous coronary intervention,PCL)的第四次革命。最初,PTCA因为早期血管弹性回缩、晚期血管负性重塑等原因,再狭窄率可达30%~50%。为解决这一问题,出现了BMS,克服了血管弹性回缩,再狭窄率得到大

关键词(KeyWords)： 生物可吸收支架;光学相干断层成像

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81370323);国家自然科学基金(81670319)

作者(Author): 吕续成,沈雳,洪斌,葛均波

参考文献(References)：

• [1]Chen JH,Wu YZ,Shen L,et al.First-in-man implantation of the XINSORB bioresorbable sirolimus-eluting scaffold in China.Chin Med J(Engl),2015,128(9):1275-1276.
• [2]Capodanno D,Gori T,Nef H,et al.Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice:early and midterm outcomes from the European multicentre GHOST-EU registry.Euro Intervention,2015,10(10):1144-1153.
• [3]Cassese S,Byrne RA,Ndrepepa G,et al.Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents:a meta-analysis of randomised controlled trials.Lancet,2016,387(10018):537-544.
• [4]Brugaletta S,Gori T,Low AF,et al.Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in STsegment elevation myocardial infarction:1-year results of a propensity score matching comparison:the BVS-EXAMINATION Study(bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial inf arction).JACC Cardiovasc Interv,2015,8(1 Pt B):189-197.
• [5]Kang SH,Chae IH,Park JJ,et al.Stent thrombosis with drugeluting stents and bioresorbable scaffolds:evidence from a network meta-analysis of 147 trials.JACC Cardiovasc Interv,2016,9(12):1203-1212.
• [6]Gao R,Yang Y,Han Y,et al.Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease:ABSORB China trial.J Am Coll Cardiol,2015,66(21):2298-2309.
• [7]Onuma Y,Serruys PW,Muramatsu T,et al.Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb everolimus-eluting fully bioresorbable vascular scaffold:optical coherence tomography assessment in the ABSORB cohort B Trial(A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).JACC Cardiovasc Interv,2014,7(12):1400-1411.
• [8]Abizaid A,Ribamar Costa J Jr,Bartorelli AL,et al.The ABSORB EXTEND study:preliminary report of the twelvemonth clinical outcomes in the first 512 patients enrolled.Euro Intervention,2015,10(12):1396-1401.
• [9]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB II):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet,2015,385(9962):43-54.
• [10]Kraak RP,Hassell ME,Grundeken MJ,et al.Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold(BVS)in real-world practice:the AMC Single Centre Real World PCI Registry.Euro Intervention,2015,10(10):1160-1168.
• [11]Caiazzo G,Kilic ID,Fabris E,et al.Absorb bioresorbable vascular scaffold:What have we learned after 5 years of clinical experience?Int J Cardiol,2015,201:129-136.
• [12]Serruys PW,Chevalier B,Sotomi Y,et al.Comparison of an everolimus-eluting bioresorbable scaffold with an everolimuseluting metallic stent for the treatment of coronary artery stenosis(ABSORB II):a 3 year,randomised,controlled,single-blind,multicentre clinical trial.Lancet,2016,388(10059):2479-2491.
• [13]Onuma Y,Serruys PW.Bioresorbable scaffold:the advent of a new era in percutaneous coronary and peripheral revascularization?Circulation,2011,123(7):779-797.
• [14]Brown AJ,Mc Cormick LM,Braganza DM,et al.Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation.Catheter Cardiovasc Interv,2014,84(1):37-45.
• [15]Verheye S,Ormiston JA,Stewart J,et al.A next-generation bioresorbable coronary scaffold system:from bench to first clinical evaluation:6-and 12-month clinical and multimodality imaging results.JACC Cardiovasc Interv,2014,7(1):89-99.
• [16]Naganuma T,Latib A,Panoulas VF,et al.Delayed disruption of a bioresorbable vascular scaffold.JACC Cardiovasc Imaging,2014,7(8):845-847.
• [17]Pan M,Romero M,Ojeda S,et al.Fracture of Bioresorbable Vascular Scaffold After Side-Branch Balloon Dilation in Bifurcation Coronary Narrowings.Am J Cardiol,2015,116(7):1045-1049.
• [18]Sato K,Panoulas VF,Naganuma T,et al.Bioresorbable vascular scaffold strut disruption after crossing with an optical coherence tomography imaging catheter.Int J Cardiol,2014,174(3):e116-e119.
• [19]R?ber L,Brugaletta S,Yamaji K,et al.Very Late Scaffold Thrombosis:Intracoronary Imaging and Histopathological and Spectroscopic Findings.J Am Coll Cardiol,2015,66(17):1901-1914.
• [20]Gutiérrez-Chico JL,Gijsen F,Regar E,et al.Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold:evidence in vivo about the abluminal healing process.JACC Cardiovasc Interv,2012,5(4):428-435.
• [21]Gomez-Lara J,Radu M,Brugaletta S,et al.Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography.JACC Cardiovasc Interv,2011,4(9):992-1001.
• [22]Ohno Y,Attizzani GF,Capodanno D,et al.Longitudinal elongation,axial compression,and effects on strut geometry of bioresorbable vascular scaffolds:insights from 2-and 3-dimensional optical coherence tomography imaging.JACC Cardiovasc Interv,2015,8(3):e35-e37.
• [23]Attizzani GF,Ohno Y,Capodanno D,et al.New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test:a note of caution on reliance to compliance charts and nominal length.Catheter Cardiovasc Interv,2015,85(4):E99-E107.
• [24]Bourantas CV,Papafaklis MI,Kotsia A,et al.Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation:an optical coherence tomography study.JACC Cardiovasc Interv,2014,7(3):315-324.
• [25]Gargiulo G,Longo G,Capodanno D,et al.Cyphering the mechanism of late failure of bioresorbable vascular scaffolds in percutaneous coronary intervention of the left main coronary artery.JACC Cardiovasc Interv,2015,8(6):e95-e97.
• [26]Farooq V,Serruys PW,Heo JH,et al.Intracoronary optical coherence tomography and histology of overlapping everolimuseluting bioresorbable vascular scaffolds in a porcine coronary artery model:the potential implications for clinical practice.JACC Cardiovasc Interv,2013,6(5):523-532.
• [27]Koskinas KC,Chatzizisis YS,Antoniadis AP,et al.Role of endothelial shear stress in stent restenosis and thrombosis:pathophysiologic mechanisms and implications for clinical translation.J Am Coll Cardiol,2012,59(15):1337-1349.
• [28]ChamiéD,Bezerra HG,Attizzani GF,et al.Incidence,predictors,morphological characteristics,and clinical outcomes of stent edge dissections detected by optical coherence tomography.JACC Cardiovasc Interv,2013,6(8):800-813.
• [29]Guo J,Chen YD,Tian F,et al.Optical coherence tomography assessment of edge dissections after drug-eluting stent implantation in coronary artery.Chin Med J(Engl),2012,125(6):1047-1050.
• [30]Ohno Y,Mangiameli A,Attizzani GF,et al.Optical coherence tomography assessment of late intra-scaffold dissection:a new challenge of bioresorbable scaffolds.JACC Cardiovasc Interv,2015,8(1 Pt A):e11-e12.
• [31]van Ditzhuijzen NS,Ligthart J,Tu S,et al.Optical coherence tomography-guided bifurcation stenting of a coronary artery dissection.Can J Cardiol,2014,30(8):956.e11-e14.
• [32]Cuesta J,Bastante T,Rivero F,et al.Coronary Pleating Mimicking Coronary Ruptures,Dissections,and Thrombi on Optical Coherence Tomography.Circ Cardiovasc Interv,2016,9(5):e003654.
• [33]Bouki KP,Sakkali E,Toutouzas K,et al.Impact of coronary artery stent edge dissections on long-term clinical outcome in patients with acute coronary syndrome:an optical coherence tomography study.Catheter Cardiovasc Interv,2015,86(2):237-246.
• [34]Nakano M,Otsuka F,Yahagi K,et al.Human autopsy study of drug-eluting stents restenosis:histomorphological predictors and neointimal characteristics.Eur Heart J,2013,34(42):3304-3313.
• [35]Radu MD,R?ber L,Kalesan B,et al.Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents:an optical coherence tomography and intravascular ultrasound study.Eur Heart J,2014,35(12):795-807.
• [36]Gori T,Jansen T,Weissner M,et al.Coronary evaginations and peri-scaffold aneurysms following implantation of bioresorbable scaffolds:incidence,outcome,and optical coherence tomography analysis of possible mechanisms.Eur Heart J,2016,37(26):2040-2049.
• [37]Malle C,Tada T,Steigerwald K,et al.Tissue characterization after drug-eluting stent implantation using optical coherence tomography.Arterioscler Thromb Vasc Biol,2013,33(6):1376-1383.
• [38]Imai M,Kadota K,Goto T,et al.Incidence,risk factors,and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation.Circulation,2011,123(21):2382-2391.
• [39]R?ber L,Togni M,Wandel S,et al.Long-term clinical outcome and anti-restenotic efficacy of drug-eluting stents:Results of the SIRTAX-LATE investigation.Am JCardiol(Suppl),2009,104:XV.
• [40]Tou?ek P,Ko?ka V,MalyM,et al.Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction:OCT data from the PRAGUE-19 study.Heart Vessels,2016,31(6):841-845.
• [41]Wu Y,Shen L,Ge L,et al.Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.Catheter Cardiovasc Interv,2016,87 Suppl 1:630-637.
• [42]Serruys PW,Onuma Y,Dudek D,et al.Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis:12-month clinical and imaging outcomes.J Am Coll Cardiol,2011,58(15):1578-1588.
• [43]Ormiston JA,Serruys PW,Onuma Y,et al.First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold:a multi-imaging modality study.Circ Cardiovasc Interv,2012,5(5):620-632.